Hepion Pharmaceuticals Inc

NASDAQ:HEPA   3:59:50 PM EDT
1.43
-0.06 (-4.03%)
4:05:48 PM EDT: $1.44 +0.01 (+0.70%)
Products, Regulatory

Hepion Pharma Announces Positive Top Line Data For Low Dose Crv431 In Phase 2A 'Ambition' Clinical Trial For Treatment Of Advanced Nash

Published: 12/29/2020 21:32 GMT
Hepion Pharmaceuticals Inc (HEPA) - Hepion Pharmaceuticals Inc. - Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose Crv431 in Phase 2a 'ambition' Clinical Trial for Treatment of Advanced Nash.
Hepion Pharmaceuticals Inc - Crv431 Demonstrated to Be Generally Safe and Well Tolerated.
Hepion Pharmaceuticals - Phase 2a Study is Continuing With Higher Dose of 225 Mg Crv431, With Nash Patient Dosing Expected to Be Completed in Q1-2021.